- Home
- SEVN vs OBIO Comparison
SEVN vs OBIO Comparison
Compare SEVN & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- OBIO
- Stock Information
- Founded
- SEVN 1986
- OBIO 2017
- Country
- SEVN United States
- OBIO United States
- Employees
- SEVN N/A
- OBIO N/A
- Industry
- SEVN Real Estate Investment Trusts
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SEVN Real Estate
- OBIO Health Care
- Exchange
- SEVN Nasdaq
- OBIO Nasdaq
- Market Cap
- SEVN 188.3M
- OBIO 151.3M
- IPO Year
- SEVN N/A
- OBIO N/A
- Fundamental
- Price
- SEVN $11.70
- OBIO $2.70
- Analyst Decision
- SEVN Strong Buy
- OBIO Strong Buy
- Analyst Count
- SEVN 4
- OBIO 5
- Target Price
- SEVN $14.50
- OBIO $15.00
- AVG Volume (30 Days)
- SEVN 57.0K
- OBIO 65.4K
- Earning Date
- SEVN 04-28-2025
- OBIO 05-12-2025
- Dividend Yield
- SEVN 11.62%
- OBIO N/A
- EPS Growth
- SEVN N/A
- OBIO N/A
- EPS
- SEVN 1.20
- OBIO N/A
- Revenue
- SEVN $29,847,000.00
- OBIO $2,638,000.00
- Revenue This Year
- SEVN $14.73
- OBIO $27.37
- Revenue Next Year
- SEVN $5.39
- OBIO $42.68
- P/E Ratio
- SEVN $10.05
- OBIO N/A
- Revenue Growth
- SEVN N/A
- OBIO N/A
- 52 Week Low
- SEVN $10.18
- OBIO $2.49
- 52 Week High
- SEVN $14.66
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- SEVN 45.15
- OBIO 37.79
- Support Level
- SEVN $10.61
- OBIO $2.75
- Resistance Level
- SEVN $12.16
- OBIO $3.26
- Average True Range (ATR)
- SEVN 0.72
- OBIO 0.43
- MACD
- SEVN 0.04
- OBIO 0.02
- Stochastic Oscillator
- SEVN 53.52
- OBIO 35.14
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.